Literature DB >> 25788494

Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma.

Ayako Masaki1, Takashi Ishida2, Yasuhiro Maeda3, Susumu Suzuki4, Asahi Ito5, Hisashi Takino6, Hiroka Ogura5, Haruhito Totani5, Takashi Yoshida5, Shiori Kinoshita5, Tomoko Narita5, Masaki Ri5, Shigeru Kusumoto5, Atsushi Inagaki7, Hirokazu Komatsu5, Akio Niimi8, Ryuzo Ueda4, Atae Utsunomiya9, Hiroshi Inagaki6, Shinsuke Iida5.   

Abstract

PURPOSE: Indoleamine 2,3-dioxygenase 1 (IDO1: IDO), an enzyme catabolizing tryptophan (Trp) into the kynurenine (Kyn) pathway, is increasingly being recognized as an important microenvironmental factor suppressing antitumor immune responses. The purpose of the present study was to determine the prognostic significance of Trp catabolism in adult T-cell leukemia/lymphoma (ATL). EXPERIMENTAL
DESIGN: We quantified serum Trp and Kyn in 96 ATL patients, 38 human T-cell lymphotropic virus type-1 asymptomatic carriers (HTLV-1 ACs), and 40 healthy adult volunteer controls. The relationships between various clinical parameters including overall survival were analyzed. IDO expression was evaluated in the affected lymph nodes of ATL patients.
RESULTS: Serum Kyn concentrations and Kyn/Trp ratios were significantly higher in HTLV-1 ACs than healthy controls. Both increased significantly with progression from HTLV-1 AC to ATL. However, there were no significant differences in the serum Trp concentrations between ATL patients, HTLV-1 ACs, and controls. IDO was possibly produced by ATL and/or cells of the microenvironment. Multivariate analyses demonstrated that a high serum Kyn/Trp ratio and high Kyn level, but not a high Trp level, were significantly independent detrimental prognostic factors in ATL, as well as in that subset of patients with aggressive variant ATL.
CONCLUSIONS: Quantification of serum Kyn and Trp is useful for predicting prognosis of an individual ATL patient. Furthermore, ATL, especially in patients with a high serum Kyn/Trp ratio, is an appropriate disease for testing novel cancer immunotherapies targeting IDO. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25788494     DOI: 10.1158/1078-0432.CCR-14-2275

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.

Authors:  Paul B Larkin; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Hiroshi Funakoshi; Toshikazu Nakamura; Robert Schwarcz; Paul J Muchowski
Journal:  Biochim Biophys Acta       Date:  2016-07-05

3.  Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas.

Authors:  April C L Bostian; Robert L Eoff
Journal:  Chem Res Toxicol       Date:  2016-08-15       Impact factor: 3.739

4.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

5.  Tryptophan catabolism in epithelial ovarian carcinoma.

Authors:  Lynelle P Smith; Benjamin G Bitler; Jennifer K Richer; Jessica L Christenson
Journal:  Trends Cancer Res       Date:  2019

6.  Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.

Authors:  Guy J Leclerc; Joanna DeSalvo; Jianfeng Du; Ningguo Gao; Gilles M Leclerc; Mark A Lehrman; Theodore J Lampidis; Julio C Barredo
Journal:  Leuk Res       Date:  2015-08-20       Impact factor: 3.156

7.  Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017).

Authors:  Lijie Zhai; Erik Ladomersky; Kristen L Lauing; Meijing Wu; Denise M Scholtens; Rohan Savoor; Bin Zhang; Jennifer D Wu; Craig Horbinski; Rimas V Lukas; David C Binder; Derek A Wainwright
Journal:  Oncoimmunology       Date:  2018-12-13       Impact factor: 8.110

8.  Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Authors:  Lijie Zhai; Erik Ladomersky; Kristen L Lauing; Meijing Wu; Matthew Genet; Galina Gritsina; Balázs Győrffy; Priscilla K Brastianos; David C Binder; Jeffrey A Sosman; Francis J Giles; Charles D James; Craig Horbinski; Roger Stupp; Derek A Wainwright
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

Review 9.  Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.

Authors:  Lijie Zhai; Stefani Spranger; David C Binder; Galina Gritsina; Kristen L Lauing; Francis J Giles; Derek A Wainwright
Journal:  Clin Cancer Res       Date:  2015-10-30       Impact factor: 12.531

Review 10.  On point in primary CNS lymphoma.

Authors:  Mazie Tsang; Joseph Cleveland; James L Rubenstein
Journal:  Hematol Oncol       Date:  2020-07-03       Impact factor: 5.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.